Description: Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Home Page: www.hikma.com
1 New Burlington Place
London,
W1S 2HR
United Kingdom
Phone:
44 20 7399 2760
Officers
Name | Title |
---|---|
Engineer Said Samih Taleb Darwazah | Executive Chairman |
Mr. Riad Ali Mishlawi | CEO & Director |
Mr. Mazen Samih Taleb Darwazah | Executive Vice Chairman & President of MENA |
Mr. Khalid Waleed Hosny Al Nabilsi CPA | Chief Financial Officer |
Patricia Bousfield | Chief Information Officer |
Mr. Guy Featherstone | Associate Director of Investor Relations |
Mr. Samuel Park | General Counsel |
Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Executive Vice President of Corporate Development and M&A |
Mr. Hussein Omar Arkhagha | Chief People Officer |
Ms. Susan Ringdal | Executive Vice President of Strategic Planning & Global Affairs |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 10.9769 |
---|---|
Trailing PE: | 29.2588 |
Price-to-Book MRQ: | 2.5106 |
Price-to-Sales TTM: | 1.8328 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 9100 |